Download

Johnson & Johnson

Johnson & Johnson has a long-term program (established in 2004) through the Johnson & Johnson Healthcare Training Fund that provides pharmaceutical supply chain management training for HIV/AIDS medicines to increase the local supply chain capabilities in the Index Countries.
Since Access to Medicine Index 2008 was released, Johnson & Johnson has entered into a licensing and commercialization agreement with Gilead Sciences, Inc. for the development of a novel fixed-dose combination (FDC) for HIV; the FDC consists of Johnson & Johnson's TMC278 and Gilead's Truvada and would be the first FDC that contains an antiretroviral from Johnson & Johnson.

During the period of analysis, Johnson & Johnson entered into discussions with UNITAID about its patent pool; Johnson & Johnson's high level of engagement and dialogue with the patent pool initiative of UNITAID is considered a best practice across the sector (among companies with relevant product portfolio).
In June 2009, Johnson & Johnson granted the Global Alliance for TB Drug Development a royalty-free license for the development of Tibotec Pharmaceutical's investigative candidate TMC-207, a novel anti-TB compound.
In addition to its innovative R&D activities for tuberculosis, Johnson & Johnson has launched R&D for a heat-stable measles vaccine.

The company's disclosure of its pricing approach for its HIV medicine PREZISTA in middle-income countries is low.
Johnson & Johnson's disclosed pricing model for PREZISTA only applies to least-developed countries and sub-Saharan Africa. Pricing for middle-income countries is negotiated on a case-by-case basis.Johnson & Johnson's overall ATM management system lacks time-bound, quantitative, short term ATM-related goals.
As many of its peers, Johnson & Johnson does not outline its public policy stance on ATM related issues such as patent extensions in Index Countries and data exclusivity.
Johnson & Johnson‘s transparency on its financial contributions to third parties in the Index Countries is low.